Aktis Oncology, Inc. (NASDAQ: AKTS) is a Healthcare company (Biotechnology) with a market capitalization of $877M. The Maz Rating grades it against the other companies in its sector.
Aktis Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.31, Aktis Oncology, Inc. trades at 70.4x sales and 2.0x book value. Over the last twelve months it generated about $12M of revenue and a net loss of $86M. It runs a gross margin of 80.0%, an operating margin of -837.5% and a net margin of -706.8%. It shows return on equity of -26.9%, return on invested capital of -20.8% and a free cash flow yield of -10.8%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 14.22. Over the past 52 weeks the share price ranged from $13.96 to $34.19, with a beta of 0.45.
Aktis Oncology, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.